{
    "nctId": "NCT04213898",
    "briefTitle": "SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer",
    "officialTitle": "SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 39,
    "primaryOutcomeMeasure": "Pathological Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Newly treated female patients aged \u226518 years and \u226460 years; 2. ECOG score 0 \\~ 1 points; 3. Pathologically confirmed, the core biopsy of breast tumor lesions identified patients with TNBC breast cancer; Note: ER and PR negatives are defined as \u2264 10% of cells expressing hormone receptors by IHC (immunohistochemistry) analysis. HER2 (human epidermal growth factor receptor 2) negative is defined as any of the following assessments: non-amplified in situ hybridization (ISH) (ratio \u2264 2.2), or IHC 0 or IHC 1+; 4. Evaluate measurable tumor lesions by ultrasound or magnetic resonance imaging (MRI) within 21 days before enrollment, size \u22652cm; 5. The main organs function normally, that is, they meet the following criteria:\n\n  1. Blood routine examination standards must meet: ANC \u22651.5 \u00d7 109 / L; PLT \u226590 \u00d7 109 / L; Hb \u226590g / L;\n  2. Biochemical examination must meet the following standards: TBIL \u2264 upper limit of normal value (ULN); ALT and AST \u2264 1.5 times the upper limit of normal value (ULN); alkaline phosphatase \u2264 2.5 times the upper limit of normal value (ULN); BUN and Cr \u2264 1.5 \u00d7 ULN and creatinine clearance \u226550 mL / min (CockcroftGault formula);\n  3. The coagulation test standard must meet: the international standardized ratio (INR) or prothrombin time (PT) \u2264 1.5 \u00d7 ULN, and the activated partial thromboplastin time (aPTT) \u2264 1.5x ULN;\n  4. Color Doppler ultrasound and echocardiography: left ventricular ejection fraction (LVEF\u226555%);\n  5. 18-lead electrocardiogram Fridericia-corrected QT interval (QTcF) for women \\<470 ms; 6. No evidence of distant metastases, including bilateral mammograms, breast ultrasounds; 7. Provide core biopsies from tumor lesions before treatment begins to confirm TNBC status and biomarker analysis; 8. For women who are not menopausal or not undergoing surgical sterilization: agree to abstinence or use an effective method of contraception during treatment and at least 7 months after the last dose during study treatment; 9. Sign the informed consent.\n\nExclusion Criteria:\n\n* 1. Inflammatory breast cancer or stage IV (metastatic) breast cancer; 2. Have previously been treated with anti-PD-1, anti-PD-L1, anti-PD-L2 drugs or drugs that target another co-inhibitory T cell receptor (eg CTLA-4, OX-40, CD137); 3\uff0e Have previously received antitumor treatment or radiation therapy for any malignant tumor, excluding cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma; 4\uff0e Also receiving anti-tumor therapy in other clinical trials, including endocrine therapy, bisphosphate therapy or immunotherapy; 5. Have undergone major breast cancer-free surgery within 4 weeks before enrollment, or the patient has not fully recovered from such surgery; 6. Severe heart disease or discomfort, including but not limited to the following:\n\n  --A history of diagnosis of heart failure or systolic dysfunction (LVEF \\<50%)\n* High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate\\> 100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-level atrioventricular block (ie Mobitz II second-degree atrioventricular block or third-degree atrioventricular block)\n\n  --Angina pectoris requiring antianginal medication\n* Clinically significant heart valve disease\n\n  --ECG shows transmural myocardial infarction\n* Poorly controlled hypertension (systolic blood pressure\\> 180 mmHg and / or diastolic blood pressure\\> 100 mmHg); 7. Have an autoimmune disease or other disease that requires systemic treatment with corticosteroids or immunosuppressive drugs (physical corticosteroid replacement therapy that allows adrenal or pituitary insufficiency); 8. A history of primary or acquired immunodeficiency (including allograft transplantation); 9. Female patients during pregnancy and lactation, female patients with fertility and a positive baseline pregnancy test, or women of childbearing age who are unwilling to take effective contraception during the entire trial and within 7 months after the last study medication; 10. have a history of (non-infectious) pneumonia, or currently have pneumonia that requires steroid therapy; 11. Active or previously documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis); 12. Known medical history of the following infections:\n\n  * Human Immunodeficiency Virus (HIV)\n  * A history of acute or chronic hepatitis B or C\n* Received live virus vaccine within 30 days of planned start of treatment. Allow use of seasonal influenza vaccines that do not contain live viruses; 13. People with a known history of allergies to the drug components of this program; a history of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 14. Suffering from a serious concomitant disease or other comorbid condition that interferes with the planned treatment, or any other condition that the investigator considers the patient unsuitable to participate in this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}